<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-20" />

<title>Medical Equipment &amp; Supplies</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/htmltools-fill-0.5.8.1/fill.css" rel="stylesheet" />
<script src="rmdlib/htmlwidgets-1.6.4/htmlwidgets.js"></script>
<link href="rmdlib/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="rmdlib/datatables-binding-0.32/datatables.js"></script>
<link href="rmdlib/dt-core-1.13.6/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="rmdlib/dt-core-1.13.6/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="rmdlib/dt-core-1.13.6/js/jquery.dataTables.min.js"></script>
<link href="rmdlib/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="rmdlib/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Index analysis. Risk metrics, constituent changes, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Medical Equipment &amp; Supplies</h1>
<h3 class="subtitle">Industry Metrics</h3>
<h4 class="date">February 20, 2026</h4>

</div>

<div id="TOC">
<ul>
<li><a href="#annual-returns">Annual Returns</a></li>
<li><a href="#cumulative-returns-and-drawdowns">Cumulative Returns and Drawdowns</a></li>
<li><a href="#sma-scenarios">SMA Scenarios</a></li>
<li><a href="#rolling-returns">Rolling Returns</a></li>
<li><a href="#constituent-shares">Constituent Shares</a></li>
<li><a href="#market-cap">Market Cap</a></li>
<li><a href="#ebit-of-industry-total">EBIT (% of Industry Total)</a></li>
<li><a href="#revenue-of-industry-total">Revenue (% of Industry Total)</a></li>
<li><a href="#ai-summaries">AI Summaries</a></li>
</ul>
</div>

<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="plots/MedicalEquipmentSupplies.fan.EQUAL_WT.png" /></p>
<p><img src="plots/MedicalEquipmentSupplies.fan.CAP_WT.png" /></p>
<p><img src="plots/MedicalEquipmentSupplies.annret.EQUAL_WT.png" /></p>
<p><img src="plots/MedicalEquipmentSupplies.annret.CAP_WT.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="plots/MedicalEquipmentSupplies.cumret.png" /></p>
<p><br />
</p>
</div>
<div id="sma-scenarios" class="section level2">
<h2>SMA Scenarios</h2>
<p><img src="plots/MedicalEquipmentSupplies.sma.cumret.EQUAL_WT.png" /></p>
<p><img src="plots/MedicalEquipmentSupplies.sma.cumret.CAP_WT.png" /></p>
<p><br />
</p>
<div id="current-distance-from-sma" class="section level3">
<h3>Current Distance from SMA</h3>
<div class="datatables html-widget html-fill-item" id="htmlwidget-ffe794ad2a6a74331d2b" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-ffe794ad2a6a74331d2b">{"x":{"filter":"none","vertical":false,"data":[["EQUAL_WT","CAP_WT"],["-2.42%","-9.48%"],["-11.68%","-20.02%"],["-18.11%","-27.89%"],["-22.9%","-34.79%"]],"container":"<table class=\"cell-border stripe\">\n  <thead>\n    <tr>\n      <th>WT<\/th>\n      <th>SMA_20<\/th>\n      <th>SMA_50<\/th>\n      <th>SMA_100<\/th>\n      <th>SMA_200<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"t","pageLength":30,"ordering":false,"columnDefs":[{"name":"WT","targets":0},{"name":"SMA_20","targets":1},{"name":"SMA_50","targets":2},{"name":"SMA_100","targets":3},{"name":"SMA_200","targets":4}],"order":[],"autoWidth":false,"orderClasses":false,"lengthMenu":[10,25,30,50,100]}},"evals":[],"jsHooks":[]}</script>
<p><br />
</p>
</div>
</div>
<div id="rolling-returns" class="section level2">
<h2>Rolling Returns</h2>
<p><img src="plots/MedicalEquipmentSupplies.roll.EQUAL_WT.png" /></p>
<p><img src="plots/MedicalEquipmentSupplies.roll.CAP_WT.png" /></p>
<p><br />
<br />
</p>
</div>
<div id="constituent-shares" class="section level2">
<h2>Constituent Shares</h2>
<p><br />
</p>
</div>
<div id="market-cap" class="section level2">
<h2>Market Cap</h2>
<div class="datatables html-widget html-fill-item" id="htmlwidget-8e001b1ab55fbbd3ac0b" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-8e001b1ab55fbbd3ac0b">{"x":{"filter":"none","vertical":false,"data":[["<a href=\"/reports02/eq-in/risk/in.POLYMED.html\" target=\"_blank\">POLYMED<\/a>","FISCHER","<a href=\"/reports02/eq-in/risk/in.LAXMIDENTL.html\" target=\"_blank\">LAXMIDENTL<\/a>","<a href=\"/reports02/eq-in/risk/in.TARSONS.html\" target=\"_blank\">TARSONS<\/a>","<a href=\"/reports02/eq-in/risk/in.FABTECH.html\" target=\"_blank\">FABTECH<\/a>","<a href=\"/reports02/eq-in/risk/in.NURECA.html\" target=\"_blank\">NURECA<\/a>"],[0.7619321791057916,0.0838746721622548,0.0614774924904682,0.04788858078197387,0.02993390947649009,0.01489316598302143],[0.6905100211949891,0.143320527260207,0.05850637664584694,0.05558779139164648,0.03760598152158875,0.01446930198572166]],"container":"<table class=\"cell-border stripe\">\n  <thead>\n    <tr>\n      <th><\/th>\n      <th>free-float<\/th>\n      <th>full-float<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"t","pageLength":6,"columnDefs":[{"targets":1,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 2, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[1,2]},{"name":"SYMBOL_LINK","targets":0},{"name":"FF_PCT","targets":1},{"name":"CAP_PCT","targets":2}],"order":[],"autoWidth":false,"orderClasses":false,"lengthMenu":[6,10,25,50,100]}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render"],"jsHooks":[]}</script>
</div>
<div id="ebit-of-industry-total" class="section level2">
<h2>EBIT (% of Industry Total)</h2>
<div class="datatables html-widget html-fill-item" id="htmlwidget-f1f37e4e6aafa7240dc3" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-f1f37e4e6aafa7240dc3">{"x":{"filter":"none","vertical":false,"data":[["<a href=\"/reports02/eq-in/risk/in.POLYMED.html\" target=\"_blank\">POLYMED<\/a>","FISCHER","<a href=\"/reports02/eq-in/risk/in.LAXMIDENTL.html\" target=\"_blank\">LAXMIDENTL<\/a>","<a href=\"/reports02/eq-in/risk/in.TARSONS.html\" target=\"_blank\">TARSONS<\/a>","<a href=\"/reports02/eq-in/risk/in.FABTECH.html\" target=\"_blank\">FABTECH<\/a>","<a href=\"/reports02/eq-in/risk/in.NURECA.html\" target=\"_blank\">NURECA<\/a>"],[16.6487127706637,26.08891244807192,3.412322256204907,11.82823521197851,null,1.106399616203745],[42.28540238913747,18.21650649739561,5.281220170753593,7.027630362614445,13.24361065571509,2.630376170470083],[42.34641053713377,26.6472456080953,6.445070533199725,9.016387404830583,12.12346576956581,3.421420147174812]],"container":"<table class=\"cell-border stripe\">\n  <thead>\n    <tr>\n      <th><\/th>\n      <th>2025-06-30<\/th>\n      <th>2025-09-30<\/th>\n      <th>2025-12-31<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"t","pageLength":6,"columnDefs":[{"targets":1,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[1,2,3]},{"name":"SYMBOL","targets":0},{"name":"2025-06-30","targets":1},{"name":"2025-09-30","targets":2},{"name":"2025-12-31","targets":3}],"order":[],"autoWidth":false,"orderClasses":false,"lengthMenu":[6,10,25,50,100]}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render"],"jsHooks":[]}</script>
</div>
<div id="revenue-of-industry-total" class="section level2">
<h2>Revenue (% of Industry Total)</h2>
<div class="datatables html-widget html-fill-item" id="htmlwidget-2ae97151d4e99ef08bf1" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-2ae97151d4e99ef08bf1">{"x":{"filter":"none","vertical":false,"data":[["<a href=\"/reports02/eq-in/risk/in.POLYMED.html\" target=\"_blank\">POLYMED<\/a>","FISCHER","<a href=\"/reports02/eq-in/risk/in.LAXMIDENTL.html\" target=\"_blank\">LAXMIDENTL<\/a>","<a href=\"/reports02/eq-in/risk/in.TARSONS.html\" target=\"_blank\">TARSONS<\/a>","<a href=\"/reports02/eq-in/risk/in.FABTECH.html\" target=\"_blank\">FABTECH<\/a>","<a href=\"/reports02/eq-in/risk/in.NURECA.html\" target=\"_blank\">NURECA<\/a>"],[46.79415340658944,3.691546953925023,5.369998496127353,11.30792712389288,null,1.557524342291028],[48.21355889800554,8.858339651518866,5.853894183302121,11.46759091949353,14.14042877785157,1.697289269886173],[52.27723906495722,12.37376898442583,6.019299293631557,12.15623569699709,14.80351961781467,2.369937342173634]],"container":"<table class=\"cell-border stripe\">\n  <thead>\n    <tr>\n      <th><\/th>\n      <th>2025-06-30<\/th>\n      <th>2025-09-30<\/th>\n      <th>2025-12-31<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"t","pageLength":6,"columnDefs":[{"targets":1,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[1,2,3]},{"name":"SYMBOL","targets":0},{"name":"2025-06-30","targets":1},{"name":"2025-09-30","targets":2},{"name":"2025-12-31","targets":3}],"order":[],"autoWidth":false,"orderClasses":false,"lengthMenu":[6,10,25,50,100]}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render"],"jsHooks":[]}</script>
<p><br />
</p>
</div>
<div id="ai-summaries" class="section level2">
<h2>AI Summaries</h2>
<div id="analyst" class="section level3">
<h3><strong>Analyst</strong></h3>
<p><em>asof: 2025-11-30 </em></p>
</div>
<div id="analysis-of-indian-medical-equipment-supplies-sector" class="section level3">
<h3>Analysis of Indian Medical Equipment &amp; Supplies Sector</h3>
<p>The provided documents (Q2/H1 FY26 earnings transcripts and announcements from key players like <strong>Poly Medicare (POLYMED)</strong>, <strong>Fischer Medical Ventures (FISCHER)</strong>, <strong>Fabtech Technologies</strong>, <strong>Tarsons Products (TARSONS)</strong>, and others) offer insights into a diverse medtech ecosystem spanning infusion/renal/cardiology/ortho devices (POLYMED), diagnostic imaging/preventive health (FISCHER), turnkey pharma/biotech engineering (Fabtech), and plastic labware (TARSONS). The sector benefits from India’s ~$15B domestic market (global ~$650B) and PLI/Make-in-India push, but faces export/export-oriented challenges. Below is a structured analysis of <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>, followed by a summary.</p>
<div id="headwinds" class="section level6">
<h6>Headwinds</h6>
<ul>
<li><strong>Export/Macro Pressures</strong>: US 50% tariffs create “no-trade zone” (POLYMED, TARSONS); Europe degrowth (-9.6% YoY, inventory overhang, Chinese dumping, Suez delays); global uncertainties (geopolitics, post-COVID sluggishness). Exports flat/declining (TARSONS 3Q degrowth despite order book).</li>
<li><strong>Domestic Competition &amp; Pricing</strong>: Intense rivalry (new entrants, MNC subcontracting locals); price commoditization (labware/devices); govt business slowdown (-14% POLYMED); GST transitions disrupting inventory (Renal segment).</li>
<li><strong>Operational/Execution</strong>: Capex ramp-up delays (TARSONS Panchla/Amta partial commissioning); high depreciation (TARSONS Rs85-105cr FY26 peak); acquisition integration (POLYMED PendraCare/Citieffe, TARSONS Nerbe flat due to German economy).</li>
<li><strong>Regulatory/Logistics</strong>: US FDA rejecting Indian lab results; EU MDR re-certification delays; freight/BL issuance issues (TARSONS exports withheld).</li>
</ul>
</div>
<div id="tailwinds" class="section level6">
<h6>Tailwinds</h6>
<ul>
<li><strong>Govt Policy Support</strong>: Ayushman Bharat, PLI schemes, National Health Mission, 200 oncology centers (expanding to 700), TB-free initiatives boost diagnostics/equipment demand (FISCHER MRI/CT growth).</li>
<li><strong>Domestic Momentum</strong>: Strong private sector uptake (POLYMED +22% YoY, domestic 17-18% H1); wallet share gains via new salesforce (100+ hires); biopharma/pharma infra investments.</li>
<li><strong>Capacity &amp; Product Expansion</strong>: Multi-company capex (POLYMED Rs250cr, TARSONS Rs550-650cr, Fabtech efficiencies); 20+ new launches (POLYMED 20 CE-marked products, FISCHER iMRI/CT, TARSONS bioprocess/cell culture).</li>
<li><strong>Acquisitions/Synergies</strong>: POLYMED adds Rs280cr revenue (Citieffe ortho, PendraCare cardio); high margins sustained (POLYMED 26.7% EBITDA, FISCHER 25-28%).</li>
<li><strong>Cash Resilience</strong>: Strong liquidity (POLYMED Rs800cr post-acq., FISCHER net cash Rs28cr); opex leverage (FISCHER 120% YoY revenue).</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6>Growth Prospects</h6>
<ul>
<li><strong>Domestic (High Confidence)</strong>: 28-30% FY26 (POLYMED); MRI/CT ~15% CAGR India (FISCHER, 500-1000 installs/yr); labware/pharma infra via wallet share (TARSONS Rs350-400cr peak from new facilities); turnkey projects (Fabtech Rs90k+cr order book, 9% QoQ growth).</li>
<li><strong>Exports/International</strong>: ROW (South Asia/Africa/ME) +13% (POLYMED); MENA/GCC medicinal independence (Fabtech Vision 2030); emerging markets for imaging/preventive (FISCHER 15-20% share aspired); post-tariff resolution US ramp-up (POLYMED/TARSONS $15-20M pipeline).</li>
<li><strong>Segment TAM Expansion</strong>: Ortho ($70B global via POLYMED acq.); diagnostics ($45-50B global, 5-6% CAGR); labware (INR1,200cr India, plastic share rising to 50%+); FY26 guidance: POLYMED 15-16% revenue, 25-27% EBITDA; FISCHER equal split imaging/preventive; Fabtech 20-25% sustained.</li>
<li><strong>Long-Term (3-5 Yrs)</strong>: 15-20% sector CAGR (import substitution, PLI); full capex utilization (TARSONS FY27-28); new verticals (POLYMED 50-80 pipeline products).</li>
</ul>
<table>
<colgroup>
<col width="15%" />
<col width="45%" />
<col width="39%" />
</colgroup>
<thead>
<tr class="header">
<th>Metric</th>
<th>FY26 Guidance (Key Cos.)</th>
<th>H1 FY26 Highlights</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue Growth</strong></td>
<td>POLYMED 15-16%; Fabtech 20-25%</td>
<td>POLYMED +5.3%; FISCHER +120%; TARSONS +3% consol.</td>
</tr>
<tr class="even">
<td><strong>EBITDA Margin</strong></td>
<td>POLYMED 25-27%; FISCHER ~25%</td>
<td>POLYMED 26.7%; FISCHER 25%; TARSONS 26.9%</td>
</tr>
<tr class="odd">
<td><strong>Order Book</strong></td>
<td>Fabtech Rs904cr (+9% QoQ); POLYMED healthy</td>
<td>Strong pipelines across.</td>
</tr>
</tbody>
</table>
</div>
<div id="key-risks" class="section level6">
<h6>Key Risks</h6>
<ul>
<li><strong>Macro/Trade</strong>: Prolonged US tariffs/EU slowdown (50%+ export exposure for some); Chinese dumping; forex volatility (rupee dep. aids Nerbe but hurts imports).</li>
<li><strong>Execution</strong>: Capex delays/ramp-up (3-5yr for TARSONS new products); debt peak (TARSONS Rs425-450cr); lumpy revenues (Fabtech project-based).</li>
<li><strong>Competition/Margins</strong>: Price wars erode margins (TARSONS domestic flat 4yrs); overcapacity in labware.</li>
<li><strong>Regulatory</strong>: US FDA/EU MDR hurdles; clinical trials (POLYMED stents).</li>
<li><strong>Sector-Specific</strong>: Disease profiling/market mapping delays (Fabtech); customer validation (1-2yrs for new products).</li>
</ul>
</div>
<div id="summary" class="section level6">
<h6>Summary</h6>
<p>The <strong>Indian Med Equipment &amp; Supplies sector</strong> (~2-3% global share) shows <strong>resilience amid headwinds</strong>, with <strong>robust domestic tailwinds</strong> (govt schemes, private demand) offsetting <strong>export drags</strong> (tariffs, competition). <strong>Growth prospects</strong> are strong (15-20% CAGR) via expansions/acquisitions/new products, targeting $20%+ topline in high-margin segments (diagnostics, ortho, labware). <strong>POLYMED/FISCHER</strong> exemplify upside (domestic/export recovery), while <strong>TARSONS</strong> highlights capex risks. <strong>Key watch</strong>: Tariff resolution, capex ROI (FY27+), competition. <strong>Overall Outlook</strong>: Positive (Buy/Hold bias) for domestic-focused players; cautious on pure exporters. Sector poised for import substitution, but 2-3yr execution critical.</p>
<p><em>Data as of Nov 2025 transcripts; actuals may vary.</em></p>
</div>
</div>
<div id="financial" class="section level3">
<h3><strong>Financial</strong></h3>
<p><em>asof: 2025-11-30 </em></p>
</div>
<div id="analysis-of-indian-medical-equipment-supplies-sector-1" class="section level3">
<h3>Analysis of Indian Medical Equipment &amp; Supplies Sector</h3>
<p>Based on the Q3/Nine Months FY25 financial results (ended Dec 31, 2024) from key listed players—<strong>Poly Medicare Ltd (POLYMED)</strong>, <strong>Laxmi Dental Ltd (LAXMIDENTL)</strong>, <strong>Tarsons Products Ltd (TARSONS)</strong>, and <strong>Nureca Ltd (NURECA)</strong>—this analysis highlights <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>. These companies represent diverse sub-sectors (infusion devices, dental products, lab consumables, home healthcare). Data is in ₹ lacs unless specified; focus is consolidated where available. Overall sector shows robust growth in revenues/profits for most (driven by Poly/Laxmi/Tarsons), but pockets of weakness (Nureca).</p>
<div id="summary-table" class="section level6">
<h6>Summary Table</h6>
<table>
<colgroup>
<col width="58%" />
<col width="41%" />
</colgroup>
<thead>
<tr class="header">
<th>Aspect</th>
<th>Key Highlights</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue Growth (9M FY25 YoY)</strong></td>
<td>+25% (Poly: +25%), +78% (Laxmi: strong post-IPO base), +47% (Tarsons), -ve (Nureca: flat/declining). Sector avg: +40-50% ex-Nureca.</td>
</tr>
<tr class="even">
<td><strong>PAT Growth (9M FY25 YoY)</strong></td>
<td>+52% (Poly), +47% (Laxmi), -40% (Tarsons), -31% loss (Nureca). Sector resilient but uneven.</td>
</tr>
<tr class="odd">
<td><strong>Market Caps (indicative)</strong></td>
<td>Poly (~₹10,000 Cr+), others mid/small-cap. Recent listings (Laxmi) boost liquidity.</td>
</tr>
<tr class="even">
<td><strong>Overall Sentiment</strong></td>
<td><strong>Positive</strong>: Export/med device boom; <strong>Caution</strong>: Operational hiccups, losses in consumer segment.</td>
</tr>
</tbody>
</table>
</div>
<div id="tailwinds-positive-drivers" class="section level6">
<h6>1. Tailwinds (Positive Drivers)</h6>
<ul>
<li><strong>Strong Revenue Momentum</strong>: Poly (9M rev ₹1,18,083 lacs, +25% YoY), Laxmi (cons ₹17,614 lacs sales, +29% YoY), Tarsons (₹2,79,723 lacs, +47%). Driven by domestic demand, exports (Poly subsidiaries in China/Netherlands/Egypt; Tarsons Germany ops).</li>
<li><strong>Profitability Surge</strong>: Poly PAT ₹24,467 lacs (+52%); Laxmi cons PAT ₹2,756 lacs (+57%). High margins from scale (Poly op. profit 22%); Laxmi aligners/lab segments strong.</li>
<li><strong>Capital Infusion</strong>: Poly QIP ₹1,000 Cr (utilized for debt repayment/investments); Laxmi IPO (₹70 Cr fresh issue, listed Jan 2025). Funds capex/inorganic growth.</li>
<li><strong>International Expansion</strong>: Tarsons Nerbe acquisition (Germany rev ₹58,624 lacs); Poly foreign subs contribute ~10-15% rev.</li>
<li><strong>Auditor Comfort</strong>: Unmodified limited review reports across all; Ind AS compliant.</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6>2. Headwinds (Challenges)</h6>
<ul>
<li><strong>Profit Declines/ Losses</strong>: Tarsons PAT down 40% YoY (₹1,957 lacs) due to high dep (₹4,247 lacs, +51%) &amp; finance costs (₹1,418 lacs, +142%); Nureca deep losses (cons PAT -₹162 lacs Q3, 9M -₹162 lacs, rev decline 4% QoQ).</li>
<li><strong>Margin Pressures</strong>: Rising employee costs (Poly +28%, Tarsons +70%); dep/amort up (Tarsons +51% from expansions). Inventory volatility (Poly +ve changes drag; Laxmi +ve).</li>
<li><strong>One-Off Hits</strong>: Tarsons ₹934 lacs provision for machinery damage (insurance pending); Laxmi discontinued ops loss ₹71 lacs.</li>
<li><strong>Demand Softness</strong>: Nureca (home healthcare) rev drop (Q3 ₹2,727 lacs vs ₹3,238 prev Q); consumer slowdown post-COVID.</li>
</ul>
</div>
<div id="growth-prospects-1" class="section level6">
<h6>3. Growth Prospects</h6>
<ul>
<li><p><strong>High (Strong Fundamentals)</strong>: | Company | Key Drivers | |———|————-| | <strong>Poly</strong> | ₹500 Cr capex for mfg; inorganic (₹250 Cr QIP allocation); single med device segment; QIP balance in MFs for deployment. 20%+ EPS growth. | | <strong>Laxmi</strong> | Post-IPO expansion (dental labs/aligners); segments: Lab (63% rev), Aligners (35%, high growth); ESOPs for talent; US subs (Laxmi Dental Lab USA). | | <strong>Tarsons</strong> | Geo-segments: India 97% rev, Germany ramp-up (20% rev); new mfg lines despite transit issues. | | <strong>Nureca</strong> | Turnaround potential via cost cuts; subs (US/India) for exports.</p></li>
<li><p><strong>Sector-Wide</strong>: Med device localization (PLI scheme tailwind); exports to US/EU (20-30% sector growth est.); capex cycle (Poly/Laxmi/Tarsons investing ₹1,500 Cr+ combined).</p></li>
</ul>
</div>
<div id="key-risks-1" class="section level6">
<h6>4. Key Risks</h6>
<table>
<colgroup>
<col width="38%" />
<col width="23%" />
<col width="38%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Impacted Cos.</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Execution/Operational</strong></td>
<td>QIP/capex delays (Poly unutilized ₹900 Cr); machinery damage/insurance (Tarsons ₹93 Cr); inventory buildup (Laxmi +₹20 Cr).</td>
<td>All</td>
</tr>
<tr class="even">
<td><strong>Financial</strong></td>
<td>High debt (Tarsons finance cost +142%); forex volatility (Tarsons/Poly foreign ops, OCI swings ₹95 lacs).</td>
<td>Tarsons, Poly</td>
</tr>
<tr class="odd">
<td><strong>Market/Demand</strong></td>
<td>Consumer slowdown (Nureca losses); competition in dental/labware (Laxmi/Tarsons).</td>
<td>Nureca, Laxmi</td>
</tr>
<tr class="even">
<td><strong>Regulatory/Compliance</strong></td>
<td>Ind AS conversions for foreign subs (auditor reliance); ESOP dilution (Laxmi/Poly). Recent CS changes (Nureca).</td>
<td>All</td>
</tr>
<tr class="odd">
<td><strong>Segment-Specific</strong></td>
<td>Discontinued ops (Laxmi ₹71 lacs loss); single-segment reliance (Poly/Nureca).</td>
<td>Laxmi</td>
</tr>
<tr class="even">
<td><strong>Macro</strong></td>
<td>Input costs (metals/plastics up 10-20%); rupee depreciation hits imports.</td>
<td>All</td>
</tr>
</tbody>
</table>
</div>
<div id="overall-sector-outlook" class="section level6">
<h6>Overall Sector Outlook</h6>
<ul>
<li><strong>Bullish Medium-Term</strong>: 20-30% CAGR potential from capex, exports, PLI incentives. Poly/Laxmi as leaders; Tarsons intl. play.</li>
<li><strong>Near-Term Caution</strong>: Nureca drag (consumer weakness); watch QIP utilization, insurance resolutions.</li>
<li><strong>Recommendation</strong>: Positive on Poly/Laxmi (buy/grow); Hold Tarsons (execution risk); Avoid Nureca (losses).</li>
</ul>
<p><em>Sources: Filed results (Feb 2025); figures standalone/consolidated as primary. Analysis as of Feb 2025 filings.</em></p>
</div>
</div>
<div id="general" class="section level3">
<h3><strong>General</strong></h3>
<p><em>asof: 2025-11-30 </em></p>
<div id="summary-analysis-indian-medical-equipment-supplies-sector" class="section level9">
<p class="heading">Summary Analysis: Indian Medical Equipment &amp; Supplies Sector</p>
<p>Using the provided documents from key players (Poly Medicare/POLYMED, Fischer Medical Ventures/FISCHER, Laxmi Dental/LAXMIDENTL, Tarsons Products/TARSONS, and Nureca/NURECA), the Indian Medical Equipment &amp; Supplies sector shows robust momentum driven by government initiatives and rising healthcare demand. However, execution delays, capex intensity, and regulatory hurdles pose challenges. Below is a structured analysis of <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>.</p>
<div id="tailwinds-positive-factors" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Factors)</strong></p>
<ul>
<li><strong>Government Support &amp; Localization</strong>: Strong policy push via “Make in India”, PLI schemes, and public procurement favoring local players (e.g., FISCHER’s AMTZ location in Andhra Pradesh leverages “Local First” policy; first indigenously manufactured 1.5T MRI with CDSCO approval).</li>
<li><strong>Rising Demand for Diagnostics &amp; Preventive Care</strong>: Chronic MRI shortages in emerging markets; NCDs (e.g., cancer, TB) driving need for screening (FISCHER’s e-HAP kiosks, SHIELD/4T4TB programs, handheld X-rays with AI &gt;95% TB accuracy).</li>
<li><strong>Technological Innovation</strong>: Disruptive tech like helium-free/open MRIs (20-25% op cost savings), AI-accelerated imaging, regenerative skin (NanoMedic), voice AI for mental health (Wonder Tech), and nutraceuticals (Nanyang Biologics). FISCHER’s full-stack (MRI/CT/X-ray/kiosks) positions it as a leader.</li>
<li><strong>Funding &amp; Listings</strong>: Recent IPOs (FISCHER NSE-listed FY25, INR 100 Cr revenue; LAXMI INR 128 Cr net proceeds utilized for debt/capex). Investor engagement (POLYMED one-on-ones) signals confidence.</li>
<li><strong>Export/Geographic Expansion</strong>: MENA/SEA focus (FISCHER rights; TARSONS Singapore sub for German ops); partnerships (e.g., FISCHER with radiologists, FlynnCare for kiosks/TB screening).</li>
</ul>
</div>
<div id="headwinds-challenges-1" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Execution Delays</strong>: IPO proceeds underutilized/idle (LAXMI: 64 Cr unspent in Q2FY26, capex delayed 6 months due to vendor changes; partial progress on machinery).</li>
<li><strong>Operational Hiccups</strong>: Short-notice changes/exigencies (POLYMED investor meets); board delays (NURECA buyback postponed due to independent directors’ unavailability).</li>
<li><strong>High Capex &amp; Debt Burden</strong>: Heavy machinery investments (LAXMI: 68 Cr capex; FISCHER R&amp;D/manufacturing expansion). Debt repayment key use of IPO funds (LAXMI 27 Cr repaid).</li>
<li><strong>Subsidiary/Overseas Dependencies</strong>: Funds routed abroad (TARSONS EUR 3M investment in Singapore sub for loans; FISCHER’s global approvals FDC/CE/CDSCO).</li>
<li><strong>Market Competition</strong>: Incumbents dominate high-end imaging; emerging players need ACR/FDA validations (FISCHER’s PICA/EMMA approvals as edge).</li>
</ul>
</div>
<div id="growth-prospects-2" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>High Double-Digit Expansion</strong>: FISCHER: FY25 INR 100 Cr revenue, strong pipeline (&gt;100 MRI units India/MENA/SEA), FY26+ scaling via CT/X-ray/kiosks/new tech (e.g., NanoMedic exclusive India/SEA rights). LAXMI: Post-capex scaling in dental devices.</li>
<li><strong>Diversification</strong>: Shift to preventive/POC diagnostics (kiosks for 50+ parameters, ECG, fundus cams); adjacencies like edtech health screening (FlynnCare schools), cancer/TB programs, nutraceuticals.</li>
<li><strong>Order Books &amp; Partnerships</strong>: FISCHER: Key radiologist/hospital deals (e.g., 1-10 MRI/CT units FY25-27); RSNA exposure (300+ interactions). Sector tailwinds: India TB elimination 2025, NCD prevention.</li>
<li><strong>M&amp;A/Investments</strong>: Strategic infusions (TARSONS sub for ops); new lines (FISCHER: 7-9.4T preclinical MRI, AI drug discovery).</li>
<li><strong>Projected Trajectory</strong>: 20-30% CAGR feasible via localization (govt orders), exports, AI/cloud integration; FY26 revenue inflection for listed peers.</li>
</ul>
</div>
<div id="key-risks-2" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="27%" />
<col width="16%" />
<col width="56%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Mitigation/Evidence from Docs</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Execution/Utilization</strong></td>
<td>Delays in capex deployment (LAXMI idle funds in FDs earning 6-7%; vendor switches).</td>
<td>Peer CA certs confirm no material deviation; FY26 deployment planned.</td>
</tr>
<tr class="even">
<td><strong>Regulatory/Approvals</strong></td>
<td>CDSCO/FDA/CE dependencies (FISCHER multiple approvals); overseas FDI/RBI nods (TARSONS).</td>
<td>Most secured (e.g., FISCHER CDSCO for MRI); no UPSI shared in meets.</td>
</tr>
<tr class="odd">
<td><strong>Financial</strong></td>
<td>Debt reliance (LAXMI/TARSONS repayments); forex exposure (EUR investments).</td>
<td>IPO proceeds fully aligned; FDs deployed for unspent funds.</td>
</tr>
<tr class="even">
<td><strong>Governance</strong></td>
<td>Board/independent director issues (NURECA postponement).</td>
<td>Compliance with Reg 30; no insider trading window closure.</td>
</tr>
<tr class="odd">
<td><strong>Market/Operational</strong></td>
<td>Exigencies/tech viability (Poly/Fischer disclaimers); competition from globals.</td>
<td>Strong pipelines; disruptive cost advantages (e.g., FISCHER 15-min scans).</td>
</tr>
<tr class="even">
<td><strong>Macro</strong></td>
<td>Policy shifts, economic slowdowns affecting govt orders/hospitals.</td>
<td>PLI/AMTZ buffers; diversified geographies.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Outlook</strong>: <strong>Bullish with cautious execution</strong>. Tailwinds from policy/tech/demand outweigh headwinds, positioning sector for 25%+ growth FY26+. FISCHER exemplifies potential (INR 100 Cr → multi-product scale), but monitor capex timelines (LAXMI) and governance (NURECA). Investors should track Q3FY26 utilization reports and order wins. No criminal/policy violations noted; all compliant with SEBI Reg 30/LODDR.</p>
</div>
</div>
</div>
<div id="investor" class="section level3">
<h3><strong>Investor</strong></h3>
<p><em>asof: 2025-11-30 </em></p>
<div id="analysis-of-indian-medical-equipment-supplies-sector-2" class="section level9">
<p class="heading">Analysis of Indian Medical Equipment &amp; Supplies Sector</p>
<p>The provided documents highlight key players in the Indian medtech sector—<strong>Poly Medicare (infusion therapy, cardio, renal, critical care, ortho)</strong>, <strong>Fischer Medical Ventures (diagnostic imaging like MRI/CT, preventive health)</strong>, <strong>Fabtech Technologies (turnkey pharma/biotech facilities)</strong>, <strong>Tarsons Products (plastic labware)</strong>, and minor insights from Laxmi Dental. These reflect a sector poised for growth amid government support but facing export and competitive pressures. Below is a structured analysis of <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>.</p>
<div id="tailwinds-positive-drivers-1" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Drivers)</strong></p>
<ul>
<li><strong>Government Support &amp; Policy Push</strong>: PLI schemes, Make in India, Ayushman Bharat, and National Health Mission driving domestic manufacturing, oncology centers (200+ planned), and TB/cancer screening. PolyMed/Fischer emphasize self-reliance in medtech.</li>
<li><strong>Robust Domestic Demand</strong>: PolyMed domestic revenue up 17-18% YoY (32% of total), private business +22%; outpacing competition via sales force addition (100+ hires FY26). Fischer/Fabtech see traction in Tier-2/3 cities and pharma infra.</li>
<li><strong>Capacity &amp; Product Expansion</strong>: PolyMed CAPEX ₹250cr (new plants operational 12-18 months); Tarsons Panchla/Amta (₹550-650cr total, bioprocess/cell culture); Fischer MRI/CT/iMRI. New launches: PolyMed 20+ CE-marked products; Tarsons PETG/roller bottles.</li>
<li><strong>Acquisitions &amp; Synergies</strong>: PolyMed’s Citieffe (ortho, ₹280cr added revenue run-rate) and PendraCare (cardio); Tarsons’ Nerbe integration for Europe footprint.</li>
<li><strong>High-Margin Segments</strong>: Diagnostics/preventive (Fischer 118% YoY revenue, 25% EBITDA); renal (PolyMed +18% YoY); pharma infra (Fabtech ₹904cr order book).</li>
<li><strong>Operational Leverage</strong>: Improving gross margins (PolyMed +137bps H1; Fischer +300bps); cash flow doubling (Tarsons 85% EBITDA-to-cash conversion).</li>
</ul>
</div>
<div id="headwinds-challenges-2" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Export Weakness</strong>: PolyMed international flat/degrowing (Europe -9.6% YoY, sequential recovery); Tarsons exports stagnant 3 quarters due to freight/BL delays, capacity constraints.</li>
<li><strong>US Tariffs (50%)</strong>: PolyMed/Tarsons face “no-trade zone”; customers shifting to Vietnam/Thailand/Malaysia. FDA rejecting Indian lab tests delays approvals (PolyMed).</li>
<li><strong>Geopolitical/Macro Pressures</strong>: Europe inventory drawdown, Chinese dumping, Suez Canal/transit delays (PolyMed); global slowdown post-COVID (Tarsons domestic flat 4 years).</li>
<li><strong>Intense Competition</strong>: Domestic price wars (Tarsons commodity perception); MNCs subcontracting locals; Chinese in Europe (PolyMed).</li>
<li><strong>High CAPEX Burden</strong>: Tarsons depreciation ₹85-105cr FY26-27 impacting PAT; debt peak ₹425-450cr consol.</li>
<li><strong>Regulatory Delays</strong>: Europe MDR/CE marks (PolyMed 20 products pipeline); CDSCO for new tech (Fischer Nanomedic).</li>
</ul>
</div>
<div id="growth-prospects-3" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>Short-Term (FY26)</strong>: PolyMed 15-16% revenue (H2 +25% to ₹1,080-1,090cr, domestic 28-30%, intl 10% incl. acquisitions); EBITDA 25-27%. Fischer explosive (120% H1 YoY). Fabtech sustained via ₹904cr order book (9% QoQ growth). Tarsons ramp-up post-Q4 commissioning.</li>
<li><strong>Medium-Term (2-3 Years)</strong>: PolyMed FY27 CAPEX continuity (₹500cr organic); US pipeline $15-20mn despite tariffs. Fischer 15-20% sector-aligned growth, equal split imaging/preventive. Fabtech MENA/GCC pharma boom (Vision 2030). Tarsons ₹350-400cr peak from new facilities (₹100-125cr existing products).</li>
<li><strong>Long-Term (3-5 Years)</strong>: Sector TAM expansion (ortho $70bn global; diagnostics $70bn by 2030); PolyMed/Tarsons full capacity utilization; exports to ROW/Europe (PolyMed 75+ CE products). Overall medtech CAGR 15-20% via PLI/import substitution.</li>
</ul>
</div>
<div id="key-risks-3" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="33%" />
<col width="20%" />
<col width="46%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Impacted Companies</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Export/Geopolitical</strong></td>
<td>US tariffs, Europe slowdown, Chinese competition – 60-70% revenue exposure for some.</td>
<td>PolyMed, Tarsons</td>
</tr>
<tr class="even">
<td><strong>Execution/CAPEX Ramp</strong></td>
<td>3-5yr utilization for new capacity/products; regulatory approvals (FDA/CE).</td>
<td>Tarsons, PolyMed, Fischer</td>
</tr>
<tr class="odd">
<td><strong>Margin Pressure</strong></td>
<td>Acquisition dilution (PolyMed 10-15% EBITDA), govt tenders (low-margin, -14% PolyMed), depreciation/debt.</td>
<td>All</td>
</tr>
<tr class="even">
<td><strong>Competition</strong></td>
<td>Local/MNC price wars; commodity perception in labware/domestic.</td>
<td>Tarsons, PolyMed</td>
</tr>
<tr class="odd">
<td><strong>Lumpy/Quarterly Volatility</strong></td>
<td>Project-based (Fabtech Q1 loss vs. Q2 profit); freight delays.</td>
<td>Fabtech, PolyMed</td>
</tr>
<tr class="even">
<td><strong>Debt &amp; Working Capital</strong></td>
<td>Peak debt ₹450cr (Tarsons); receivables 80-150 days (PolyMed/Fabtech).</td>
<td>Tarsons, Fabtech</td>
</tr>
</tbody>
</table>
</div>
<div id="overall-summary" class="section level12">
<p class="heading"><strong>Overall Summary</strong></p>
<p>The Indian medtech sector shows <strong>resilience and structural growth</strong> (15-20% CAGR potential) fueled by domestic tailwinds (PLI/govt schemes, 28-30% growth in key players) and capacity expansions, but <strong>exports (50-70% for leaders) face severe headwinds</strong> from tariffs/China/Europe slowdowns, capping FY26 guidance to 15-16% overall. <strong>Growth hinges on new products/acquisitions</strong> (e.g., PolyMed ortho/cardio, Fischer diagnostics), with <strong>H2 FY26 recovery expected</strong> via domestic momentum and intl green shoots. <strong>Risks are execution-heavy</strong> (CAPEX ramp, debt), balanced by strong balance sheets (PolyMed ₹800cr cash post-acquisitions) and order books. Sector outlook: <strong>Bullish domestic, cautious exports</strong>; investors should monitor tariff resolutions and Q4 ramp-ups for inflection.</p>
</div>
</div>
</div>
<div id="meeting" class="section level3">
<h3><strong>Meeting</strong></h3>
<p><em>asof: 2025-12-03 </em></p>
</div>
<div id="analysis-of-indian-medical-equipment-supplies-sector-3" class="section level3">
<h3>Analysis of Indian Medical Equipment &amp; Supplies Sector</h3>
<p>Based on the provided documents from key players—<strong>Poly Medicare Limited (POLYMED)</strong>, <strong>Fischer Medical Ventures Limited (FISCHER)</strong>, <strong>Fabtech Technologies Limited (FABTECH)</strong>, <strong>Tarsons Products Limited (TARSONS)</strong>, and <strong>Nureca Limited (NURECA)</strong>—this analysis covers the sector’s <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>. These companies represent diverse sub-segments (disposables, ventures/equipment, pharma machinery, lab products, home healthcare). Insights are drawn from Q2/H1 FY26 financials (ending Sep 2025), AGMs, board outcomes, borrowing approvals, and strategic moves. The sector shows resilience amid expansion but faces execution and macro challenges.</p>
<div id="tailwinds-positive-drivers-2" class="section level6">
<h6><strong>Tailwinds (Positive Drivers)</strong></h6>
<ul>
<li><strong>Strong Revenue Momentum &amp; Export Focus</strong>:
<ul>
<li>FABTECH: Robust H1 revenue (₹189 Cr standalone; ₹189 Cr consolidated), driven by exports (UAE 46%, Saudi 21%, Rest of World 32%). Pharma turnkey projects signal sustained demand.</li>
<li>POLYMED: Declared ₹3.5/share dividend (70% payout); FY25 financials adopted, indicating stable operations.</li>
<li>FISCHER: Q2/H1 revenue up (standalone ₹11.97 Cr; consolidated ₹109 Cr), with subsidiaries contributing (e.g., Time Medical).</li>
<li>TARSONS: Steady revenue (H1 ₹193 Cr consolidated), supported by lab products.</li>
</ul></li>
<li><strong>Capital Raising &amp; Expansion Appetite</strong>:
<ul>
<li>POLYMED: Borrowing limits hiked to ₹1,000 Cr (from ₹400 Cr) + charges on assets; new Executive Director (Pankaj Gupta) for operations scaling.</li>
<li>FABTECH: Post-IPO (Oct 2025), funds for growth; H1 EBITDA positive despite Q1 loss.</li>
<li>FISCHER: New Independent Directors (international expertise); postal ballot for approvals.</li>
</ul></li>
<li><strong>M&amp;A &amp; Global Footprint</strong>:
<ul>
<li>TARSONS/FISCHER: Subsidiaries in Singapore, Germany, Philippines, UAE enhance forex revenue (e.g., TARSONS forex OCI loss but Germany ops).</li>
<li>Compliance upgrades (cost/secretarial auditors) signal governance for growth.</li>
</ul></li>
</ul>
</div>
<div id="headwinds-challenges-3" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<ul>
<li><strong>Profitability Volatility</strong>:
<ul>
<li>FISCHER/NURECA: Q2 losses (standalone ₹0.84 Cr/₹3.14 Cr PAT loss); high finance costs (₹2.43 Cr/₹0.61 Cr).</li>
<li>FABTECH: Q1 loss (₹6.20 Cr pre-tax); inventory buildup, forex impacts.</li>
<li>TARSONS: Modest H1 PAT (₹5.1 Cr vs. ₹14 Cr YoY); forex OCI drag (₹8.6 Cr loss).</li>
</ul></li>
<li><strong>High Costs &amp; Margins Pressure</strong>:
<ul>
<li>Depreciation/finance costs elevated (e.g., POLYMED/FABTECH capex-heavy; FISCHER ₹1.59 Cr finance).</li>
<li>Working capital strain: Rising receivables (FABTECH ₹154 Cr), inventories (FISCHER ₹52 Cr).</li>
</ul></li>
<li><strong>Macro/Operational</strong>:
<ul>
<li>Forex volatility (TARSONS ₹8.5 Cr OCI loss).</li>
<li>subdued domestic demand (NURECA revenue ₹4.7 Cr Q2).</li>
</ul></li>
</ul>
</div>
<div id="growth-prospects-4" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<ul>
<li><strong>Capex &amp; Capacity Expansion</strong> (High):
<ul>
<li>POLYMED: ₹1,000 Cr borrowing for growth; cost audit for FY26 signals scaling.</li>
<li>FABTECH: Export-led (geos: Middle East/Africa); post-IPO capex in pharma equipment.</li>
<li>FISCHER: Ventures arm with 10+ subsidiaries (e.g., FMV Global); H1 revenue +YoY.</li>
</ul></li>
<li><strong>International Diversification</strong> (Medium-High):
<ul>
<li>TARSONS: Germany/Singapore ops (H1 ₹19 Cr revenue); lab products tailwind from R&amp;D spend.</li>
<li>FISCHER/FABTECH: UAE/Saudi focus amid regional healthcare push.</li>
</ul></li>
<li><strong>Sector Tailwinds</strong>: PLI scheme, Ayushman Bharat, exports (Make in India); medtech market to $50 Bn by 2030 (CAGR 15%).</li>
<li><strong>Outlook</strong>: H1 FY26 aggregate revenue ~₹400 Cr+; PAT mix (losses offset by POLYMED/FABTECH stability). EBITDA margins 8-12%; 15-20% sector CAGR feasible with capex.</li>
</ul>
</div>
<div id="key-risks-4" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="22%" />
<col width="20%" />
<col width="26%" />
<col width="31%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Category</strong></th>
<th><strong>Description</strong></th>
<th><strong>Mitigants/Evidence</strong></th>
<th><strong>Impact (High/Med/Low)</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Debt &amp; Liquidity</strong></td>
<td>High borrowings (POLYMED ₹1,000 Cr limit; FABTECH/FISCHER short-term debt).</td>
<td>Cash positives (FABTECH ₹44 Cr ops cash); IPO inflows.</td>
<td><strong>High</strong></td>
</tr>
<tr class="even">
<td><strong>Forex &amp; Geo Exposure</strong></td>
<td>40-50% export rev (FABTECH/FISCHER); OCI losses (TARSONS ₹8.6 Cr).</td>
<td>Hedging assumed; diversified geos.</td>
<td><strong>High</strong></td>
</tr>
<tr class="odd">
<td><strong>Execution/Integration</strong></td>
<td>Subsidiary losses (FISCHER/TARSONS overseas); M&amp;A (Nureca scheme).</td>
<td>New directors (Fischer); auditors.</td>
<td><strong>Medium</strong></td>
</tr>
<tr class="even">
<td><strong>Regulatory/Compliance</strong></td>
<td>AGM approvals (directors/borrowings); SEBI scrutiny post-IPO.</td>
<td>Ongoing filings.</td>
<td><strong>Medium</strong></td>
</tr>
<tr class="odd">
<td><strong>Demand/Cyclical</strong></td>
<td>Pharma/lab slowdown (NURECA losses); inventory risks.</td>
<td>Dividend stability (POLYMED).</td>
<td><strong>Medium</strong></td>
</tr>
<tr class="even">
<td><strong>Profit Volatility</strong></td>
<td>Q-o-Q swings (FABTECH Q1 loss).</td>
<td>H1 recovery trends.</td>
<td><strong>Low-Medium</strong></td>
</tr>
</tbody>
</table>
</div>
<div id="summary-1" class="section level6">
<h6><strong>Summary</strong></h6>
<ul>
<li><strong>Overall Sector Outlook</strong>: <strong>Moderately Positive</strong>. Tailwinds from exports (Middle East/Europe), capex (₹1,000+ Cr plans), and M&amp;A outweigh headwinds. H1 FY26 shows revenue resilience (~10-20% YoY in key firms) but PAT pressured by costs/forex (aggregate ~₹20-30 Cr). Growth to 15%+ CAGR via PLI/global ops; monitor debt (D/E 0.3-0.5x).</li>
<li><strong>Investment Thesis</strong>: Buy POLYMED/FABTECH (stable/expansion); Hold FISCHER/TARSONS (turnaround potential); Avoid NURECA (losses).</li>
<li><strong>Valuation Context</strong>: Sector P/E ~25-35x; focus on EBITDA/debt metrics for FY26.</li>
</ul>
<p><em>Data as of Oct-Nov 2025 disclosures; assumes no major macro shocks.</em></p>
</div>
</div>
<div id="press-release" class="section level3">
<h3><strong>Press Release</strong></h3>
<p><em>asof: 2025-12-03 </em></p>
<div id="summary-analysis-indian-medical-equipment-supplies-sector-1" class="section level9">
<p class="heading">Summary Analysis: Indian Medical Equipment &amp; Supplies Sector</p>
<p>Based on the provided press releases from key players (Poly Medicare Ltd, Fischer Medical Ventures Ltd, Laxmi Dental Ltd, Fabtech Technologies Ltd, and Nureca Ltd), the Indian Medical Equipment &amp; Supplies sector exhibits robust momentum driven by international expansion, strategic acquisitions, digital innovation, and financial recovery. These announcements highlight a mix of M&amp;A activity, export-led growth, and profitability improvements amid a push into high-growth segments like orthopaedics, diagnostics, and dental tech. Below is a structured analysis of <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>.</p>
<div id="tailwinds-positive-drivers-3" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Drivers)</strong></p>
<ul>
<li><strong>International Expansion &amp; Partnerships</strong>: Polymed’s €31M acquisition of Citieffe Group provides entry into global orthopaedics (trauma/extremities) with established presence in US, Italy, Mexico, and 25+ countries. Fischer’s USD 6.5M Indonesia TB partnership (250 AI X-ray units) marks entry into Southeast Asia’s public health initiatives.</li>
<li><strong>Strong Revenue &amp; Profitability Growth</strong>: Laxmi Dental reported record Q2FY26 revenue (+26.5% YoY), H1 +18.1% YoY; Nureca achieved H1 revenue +40% YoY, Q2 PAT +853% YoY, signaling turnaround via cost optimization and quick commerce.</li>
<li><strong>Strategic Synergies &amp; Digital Focus</strong>: Polymed leverages manufacturing scale for cost synergies; Laxmi pushes scanners (+94.7% YoY units) for digital dentistry; Fischer emphasizes AI-powered diagnostics. Fabtech clarifies global life sciences infra focus (62 countries).</li>
<li><strong>Resilient Segments</strong>: Orthopaedics (fastest-growing, resilient), dental labs/aligners (+29.9% YoY for Laxmi), and home healthcare/wellness (Nureca) benefit from rising awareness, regulatory tailwinds, and exports to 95+ countries (Laxmi).</li>
</ul>
</div>
<div id="headwinds-challenges-4" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Margin Compression</strong>: Laxmi’s gross margins dipped to 68.5% (from 75.7% YoY) due to low-margin scanner sales and higher employee/ESOP costs (₹16.8Mn Q2, projected ₹63.4Mn FY26). EBITDA margins stable but adjusted for non-cash items.</li>
<li><strong>Competitive &amp; Market Pressures</strong>: Laxmi notes aligner segment stagnation (Bizdent flat YoY due to competition); global uncertainties impact performance despite growth.</li>
<li><strong>Comparability Issues</strong>: Exceptional gains (e.g., Laxmi’s ₹66.2Mn property sale in H1FY25) inflate prior-year bases, masking underlying trends.</li>
<li><strong>Execution in New Ventures</strong>: Kids-E-Dental (Laxmi JV) faces registration delays in international markets, tempering near-term growth.</li>
</ul>
</div>
<div id="growth-prospects-5" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>High-Potential Segments</strong>: Orthopaedics platform (Polymed: extremities/trauma, joints entry planned); digital dentistry/AI (Laxmi scanners/aligners, Fischer X-rays); cleanroom infra (Fabtech for pharma/biotech/semicon); home healthcare (Nureca quick commerce).</li>
<li><strong>Geographic &amp; Channel Expansion</strong>: US scale-up (Polymed hiring sales reps for premium pricing); Indonesia pilot (Fischer); India manufacturing/localization for cost advantages (Polymed/Citieffe). Exports leverage Polymed’s 125-country reach and Laxmi’s dental export leadership.</li>
<li><strong>Synergies &amp; Innovation</strong>: Polymed’s R&amp;D/manufacturing integration (45 patents, EU MDR/FDA cleared); Laxmi’s automation/R&amp;D investments; projected multi-year growth via orthopaedics adjacencies, digital transformation, and market consolidation.</li>
<li><strong>Financial Trajectory</strong>: H1FY26 trends (e.g., Nureca PAT +276% YoY) suggest sustained double-digit revenue growth, with EBITDA margins stabilizing at 15-18%.</li>
</ul>
</div>
<div id="key-risks-5" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<ul>
<li><strong>Regulatory &amp; Closing Conditions</strong>: Polymed acquisition subject to approvals (4-8 weeks); JV performance tied to registrations (Laxmi Kids-E-Dental).</li>
<li><strong>Integration &amp; Execution</strong>: Post-acquisition synergies (e.g., Polymed’s US expansion, India outsourcing) carry M&amp;A risks; management continuity (Citieffe CEO retained) untested.</li>
<li><strong>Macro/External Factors</strong>: Disclaimers highlight economic volatility, competition, currency fluctuations (EUR-INR deals), geopolitical issues (global uncertainties), and regulatory changes (SEBI/Ind AS norms).</li>
<li><strong>Financial/Operational</strong>: Unaudited results subject to change; reliance on pilots (Fischer); non-cash ESOPs and exceptional items distort metrics; sector vulnerability to supply chain disruptions or demand softness in exports.</li>
</ul>
<p><strong>Overall Outlook</strong>: The sector is poised for strong growth (15-40% YoY revenue potential) fueled by global forays and innovation, outweighing near-term margin pressures. Companies like Polymed and Laxmi exemplify proactive strategies, but success hinges on execution amid regulatory/macro risks. Investors should monitor Q3FY26 results and acquisition closures for confirmation.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
